NCT03110757View on ClinicalTrials.gov

A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 20, 2018

Primary Completion Date

November 14, 2019

Study Completion Date

November 14, 2019

Conditions

Schistosomiasis

Interventions

BIOLOGICAL

GLA-AF

Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist

BIOLOGICAL

Hepatitis B Virus Vaccine (Recombinant)

A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.

BIOLOGICAL

Sm-TSP-2/Alhydrogel

Trial Locations (1)

Unknown

Americaninhas Vaccine Center, Novo Oriente

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03110757 - A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults | Biotech Hunter | Biotech Hunter